News for Nuformix plc (NFX.L)

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Posts no revenue in the six months ended March 31, unchanged from a year earlier. Pretax loss...

Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further protections for its fibrosis and oncology technology. Nuformix is a London-based...

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million...

The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ---------- Sareum Holdings PLC - Cambridge-based biotechnology... | May 18, 2023

The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: ---------- Sabien Technology Group PLC - technology company, focused... | March 27, 2023

Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs. Nuformix is a... | December 13, 2022

Read Nuformix (LON:NFX) Stock Price Down 8.1% at ETF Daily News

Read Nuformix (LON:NFX) Shares Down 16.7% at ETF Daily News